GlassScriptPhysician profile
Joseph F Avey
NPI 1396732970
$3,063.71
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $742 · 2020: $484 · 2021: $317 · 2022: $218 · 2023: $527 · 2024: $776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,302.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $638.56 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $589.63 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $257.31 | 2020-2024 | Jardiance, Mounjaro, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.47 | 2019-2020 | |
| Glaxosmithkline, LLC. | $181.62 | 2019-2024 | Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $169.05 | 2019-2023 | |
| Merz North America, INC. | $156.54 | 2019-2024 | Xeomin |
| Boston Scientific Corporation | $136.43 | 2020-2024 | Watchman Flx |
| Abbvie INC. | $129.32 | 2021-2024 | Vraylar |
| Vanda Pharmaceuticals INC. | $100.32 | 2023-2024 | Hetlioz, Fanapt |
| Abbott Laboratories | $88.62 | 2021-2024 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $84.68 | 2019 | |
| Pfizer INC. | $81.89 | 2020-2024 | |
| Amarin Pharma, INC. | $69.12 | 2020-2021 | |
| Dexcom, INC. | $43.67 | 2022-2023 | Dexcom G6 Transmitter |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $40.59 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $36.61 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $16.91 | 2019 | |
| Edwards Lifesciences Corporation | $16.36 | 2023 | Sapien 3 Ultra Resilia |
| Optinose US, INC. | $16.21 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.74 | 2024 | Nuedexta |
| Antares Pharma, INC. | $12.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Avey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.